An Introduction to Thrombosis
Thrombosis refers to the formulation of a thrombus within a blood vessel, disrupting the normal blood flow through the circulatory system. Anticoagulation therapy with vitamin K-antagonists such as warfarin with heparin was the long-standing gold-standard treatment for thrombotic conditions. However, the introduction of direct oral anticoagulants changed the treatment paradigm and are now the first-line treatment of choice for eligible patients.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio.
David Berg, ESC 2022: Antithrombotic therapy for patients in critical care with COVID-19, the COVID-PACT study
The COVID-PACT study focused on critically ill patients with coronavirus disease 2019 (COVID-19), assessing the use of antithrombotic therapy. In this touchCARDIO interview, we speak with Dr David Berg (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the purpose and design of the COVID-19 study and how the outcomes will implicate […]
David Berg, ESC 2022: Unmet needs in the prevention of thrombotic events in patients with COVID-19
Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Increased risk of thrombotic events is seen in patients infected with SARS-CoV-2, which is higher in patients needing critical care. In this touchCARDIO interview, we speak with Dr David Berg (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, […]
A Review of the Past, Present and Future of Cancer-associated Thrombosis Management
Heart International. 2022;16(2):117–23 DOI: https://doi.org/10.17925/HI.2022.16.2.117
In this article, we review prior and recent landmark studies that have directed the treatment of cancer-associated thrombosis (CAT), discuss specific factors that influence anticoagulant choice, and explore ongoing trials that may impact treatment in the future. Older data estimated less than 1% of patients with malignancy developed venous thromboembolism (VTE), but more recent data […]
Problems that occur when varicose veins go untreated
Dr Yan Katsnelson, Founder, CEO, USA Vein Clinics Dr Yan Katsnelson is an entrepreneur, highly skilled cardiac surgeon, business owner, and philanthropist. He is the founder and CEO of USA Vein Clinics, which is part of USA Clinics Group – the parent company of USA Fibroid Centers, USA Vascular Centers, and USA Oncology Centers. Dr […]
Andexanet Alfa and its Clinical Application
Heart International. 2020;14(1):20-3 DOI: https://doi.org/10.17925/HI.2020.14.1.20
The factor Xa (FXa) inhibitors apixaban, rivaroxaban and edoxaban, together with the thrombin inhibitor dabigatran, are collectively referred to as non-vitamin K antagonist (or direct) oral anticoagulants (NOACs). FXa inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation,1 and for the treatment and prevention of deep vein thrombosis and pulmonary embolism.2,3 In patients […]
Venous Insufficiency in 2019 – An Update on Interventional Medicines and Procedures
Highlights from the 15th annual Complex Cardiovascular Therapeutics: Advanced Endovascular and Coronary Intervention Global Summit (C3), Hilton Bonnet Creek, Orlando, FL, US, 23–6 June 2019 — Focus on venous insufficiency Chronic venous insufficiency, resulting in abnormally high blood pressure in the veins of the extremities, leads to clinical outcomes associated with greatly reduced quality of […]
Improved Dosing and Administration of Rivaroxaban when Prescribed by a Cardiologist
Heart International. 2019;13(1):24–7 DOI: https://doi.org/10.17925/HI.2019.13.1.24
Rivaroxaban is a direct factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Furthermore, it is prescribed for risk reduction and prophylaxis for DVT and PE following hip or knee replacement surgery and […]
Purvi Parwani, Mamas Mamas, Martha Gulati, ESC 2018 – Social Media and Cardiology
Dr Purvi Parwani (Assistant Professor of Medicine, Loma Linda University Health, Loma Linda, CA, USA), Professor Mamas Mamas (Professor of Cardiology, University of Keele, Keele, UK) and Dr Martha Gulati (Head of Cardiology, University of Arizona College of Medicine, Phoenix, AZ, USA) discuss social media in cardiology. Filmed at ESC 2018, Munich. View more content […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!